Podcasts about geographic

In this episode, we discuss Chris's career transition from custom construction to financial services, the business opportunity in financial literacy education, and how families can build generational wealth through proper licensing and planning. Key Topics Discussed Chris's Career Journey 20+ years as a custom builder and general contractor in Toronto Notable projects: National Ballet, Casa Loma, Ontario Art Gallery, Casino Rama, luxury homes in Bridal Path and Forest Hill Challenges of relocating construction business from Ontario to BC The decision to transition careers at 45 years old The Career Transition Moving from construction to financial services Getting licensed through Insurance Council of British Columbia Completing provincial-level exams at Okanagan College The intimidation and pressure of returning to formal education in mid-40s The Business Opportunity Three pathways: personal finance management, one-on-one client consulting, or building a team/agency Teaching financial literacy to Canadian families Flexibility to work from home and control your own schedule Ability to pass business to family members (spouse, children) - keeping it as generational wealth Why This Matters Now Rising cost of living outpacing wage increases Mortgage rates doubling for many families Need for additional income streams Opportunity to learn financial literacy while earning The Licensing Process Provincial-level certification through Insurance Council of British Columbia Post-secondary education requirement (Okanagan College) Not a weekend course - legitimate professional designation Minimum 70% passing grade required Family Legacy Component Licensed business can transfer to spouse and children Keeps client relationships within the family unit Different from traditional firms where clients "roll up" to the company Creates true generational wealth opportunity Work-Life Balance Benefits No commuting (Chris previously spent ~1 day/week in vehicle) Flexible schedule for family events and activities Ability to work while traveling Geographic freedom - clients across Canada via virtual meetings Success Stories Rebecca Matthews: Went from multiple six figures in debt to running one of the fastest-growing agencies, earning $250K/year Team members earning from $500-2000/month part-time to $250K+ full-time Couples working together successfully in the business   Let's dive in! Thank you for joi ning us today. If you could rate, review & subscribe, it would mean the world to me! While you're at it, take a screenshot and tag me @jennpike to share on Instagram – I'll re-share that baby out to the community & once a month I'll be doing a draw from those re-shares and send the winner something special! Click here to listen: Apple Podcasts – CLICK HERESpotify – CLICK HERE Free Resources: Free Perimenopause Support Guide | jennpike.com/perimenopausesupport Free Blood Work Guide | jennpike.com/bloodworkguide The Simplicity Sessions Podcast | jennpike.com/podcast Get 20% on thewalkingpad.com using code "JENNPIKE20" Get discounts at happybumco.com using code "JENNPIKE" *code doesn't apply with Black Friday sale* Programs: Ignite: Your 8-Week Body Transformation Program | https://jennpike.com/ignite The Peri & Menopause Project  - Join the Waitlist | jennpike.com/theperimenopauseproject Synced Virtual Fitness Studio | jennpike.com/synced Services: Work With Jenn | https://jennpike.com/work-with-jenn/ Functional Testing | jennpike.com/testing-packages Business Mentorship | The Audacious Woman Mentorship:  jennpike.com/theaudaciouswoman Connect with Jenn: Instagram | @jennpike Facebook | @thesimplicityproject YouTube | Simplicity TV Website | The Simplicity Project Inc. Connect with Chris: Instagram | @chrisborsellino Finance Discovery Session | Book Here Have a question? Send it over to hello@jennpike.com and I'll do my best to share helpful insights, thoughts and advice.

The Tournament of Champions continues apace this week, as we finish off the quarterfinals and the semifinals and get ready for next week's finals by...watching an exhibition game. We have some thoughts on that as well as some of the stellar gameplay this week including a "Welcome to Next Year's JIT" performance from Tom Devlin and a down-to-the-wire finish between Cameron Berry and Paolo Pasco. Emily also LOVES a geography category this week, John receives an extremely weird heckle, and Fox News gets in on the Jeopardy! reporting game. Plus, we dive deep on Jean-Paul Marat's murderer, Charlotte Corday. If you want to murder some more Jeopardy! content, you can head on over to our Patreon for a bunch of bonus content. You'll get immediate access to our entire back catalogue, our wonderful Discord (with several J! champs hanging out in there), and a brand-new bonus episode every month, like last week's, which featured the JIT's Alison Betts and Drew Goins playing a rock and metal board to help them prepare. Join today at patreon.com/jeopardypodcast. SOURCE: The Science Survey: "The Angel of Assassination: A Profile on Charlotte Corday" by Winnie Huang Special thank you as always to the Jeopardy! Fan and J-Archive. This episode was produced by Producer Dan. Music by Nate Heller. Art by Max Wittert.

Today we are breaking down Games Workshop. This episode is another examination of the business of IP. Whether it's Disney, Electronic Arts, or Nintendo, there are so many businesses built around core IP. And while Games Workshop and its Warhammer franchise may not be as familiar to our North America listeners - this episode will tell you why that may be changing very soon. My guest is Todd Wenning, President and CIO of KNA Capital. Todd shares his own personal story uncovering Games Workshop many years ago, he gets into the fun evolution of this business which ties into the vertical integration today, and he shares what lies ahead as awareness of Warhammer's loyal enthusiasts welcome more into their world. For the full show notes, transcript, and links to the best content to learn more, check out the episode page⁠⁠⁠⁠⁠⁠⁠ here.⁠⁠⁠⁠⁠⁠⁠ — This episode is brought to you by⁠⁠⁠⁠ ⁠Portrait Analytics⁠⁠⁠⁠⁠ - your centralized resource for AI-powered idea generation, thesis monitoring, and personalized report building. Built by buy-side investors, for investment professionals. We work in the background, helping surface stock ideas and thesis signposts to help you monetize every insight. In short, we help you understand the story behind the stock chart, and get to "go, or no-go" 10x faster than before. Sign-up for a free trial today at⁠⁠⁠⁠ ⁠portraitresearch.com⁠⁠⁠⁠⁠ — Business Breakdowns is a property of Colossus, LLC. For more episodes of Business Breakdowns, visit⁠⁠⁠⁠⁠⁠⁠ colossus.com/episodes⁠⁠⁠⁠⁠⁠⁠. Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠). Timestamps  (00:00:00) Welcome to Business Breakdowns (00:03:55) Introduction to Games Workshop  (00:05:31) History of the Warhammer IP  (00:09:14) Games Workshop's Evolution  (00:10:59) Warhammer Retail Stores  (00:12:37) The Numbers Behind Warhammer's Popularity  (00:14:03) Geographic and Demographic Concentration  (00:16:36) Competition from Other Games & Hobbies  (00:18:49) Events and Community: Hidden Network Effects  (00:19:48) Margins and Cash Generation  (00:21:31) Growth Drivers & Prime Potential  (00:24:51) Licensing Model & Tariff Volatility  (00:26:49) Why the Business is Defensible  (00:28:33) The Relevance Risk  (00:31:43) Games Workshop's Unique Flat Structure  (00:32:52) Capital Allocation & Dividend Focus  (00:34:16) Valuing Games Workshop  (00:35:25) Three Man Risks for the Business  (00:38:33) Riches in Niches & Other Lessons

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Geography should never determine whether a patient lives or dies.Our next guest, Dr. Sarah Matt, is on a mission to make that vision a reality.A surgeon turned health technology strategist, Sarah has spent over two decades breaking down the barriers that separate patients from care.From leading Oracle's $28 billion Cerner integration to architecting the first U.S. remote robotic surgery network, she's been at the forefront of healthcare's digital transformation.Now, as a national bestselling author of The Borderless Healthcare Revolution, Sarah is equipping healthcare leaders with a practical framework to eliminate physical, financial, cultural, digital, and trust barriers to care.Join us to discover how we can build a truly borderless healthcare system. Let's go!Episode Highlights:Five Pillars of Access: Physical, financial, cultural, digital, and trust barriers—with cultural and trust most overlookedFrom Bedside to Billions: Sarah left the OR to impact millions through technology instead of 20 patients a day2026 is the Year of Catch Up: Fix data governance and interoperability before AI can deliver real resultsActionable Over Theoretical: Every chapter includes a builder's box and checklist for immediate actionNew Leadership Required: Leaders must think faster, embrace uncertainty, and operate in the gray zoneAbout our Guest:Sarah Matt, MD, MBA, is a surgeon turned health technology strategist, author, and speaker. Her work focuses on how digital tools, from remote surgery to telemedicine to AI, can expand access to healthcare and eliminate the traditional boundaries that separate patients from care.With over two decades of experience at the intersection of medicine and innovation, Dr. Matt has held leadership roles at Oracle Health, NextGen, and multiple health tech startups. She has designed and deployed systems that reach patients around the world, including hard-to-serve and underserved populations.A practicing physician, Dr. Matt continues to treat patients in rural and charity-based settings, keeping her closely connected to the human side of healthcare access. She speaks widely at healthcare and technology conferences and has appeared on national panels about artificial intelligence, care delivery reform, and digital transformation. She is also the author of The Borderless Healthcare Revolution: The Definitive Guide to Breaking Geographic Barriers Through Technology.A graduate of Cornell University, SUNY Upstate Medical University and UT Austin's McCombs School of Business, she blends clinical acumen with deep technical knowledge to challenge the status quo and to reimagine what healthcare can look like when geography no longer dictates your care.Links Supporting This Episode: Dr. Sarah Matt Website: CLICK HERE

In this episode of Excess Returns, Redfin Chief Economist Daryl Fairweather joins Matt Zeigler to unpack what she calls the Great Housing Reset. Rather than a housing crash or correction, Fairweather argues the market is entering a multi year transition toward something more normal, where incomes gradually catch up to home prices and affordability improves at the margin. The conversation covers mortgage rates, supply constraints, regional housing dynamics, climate risk, policy tradeoffs, and how AI is reshaping real estate decisions for buyers, renters, and investors.Topics covered in this episode• Why the current housing market is a reset, not a crash or correction• How income growth outpacing home price growth could slowly improve affordability• Mortgage rate dynamics and why rates may stay near the low 6 percent range• The mortgage rate lock in effect and why inventory may take years to normalize• Regional housing trends including the Midwest, Northeast, Sunbelt, and tech hubs• The role of wages, rents, and affordability for Gen Z and first time homebuyers• Investor activity, rental markets, and the outlook for housing as an investment• Immigration, foreign buyers, and local market distortions• Multi generational living, ADUs, and creative housing solutions• Housing policy ideas that actually address supply constraints• Why demand side policies like 50 year mortgages miss the real problem• Climate risk, insurance costs, and total cost of home ownership• How AI and conversational search are changing the home buying process• The future of MLS consolidation and real estate market structure• Practical guidance for renters, buyers, and homeowners looking ahead to 2026Timestamps00:00 Introduction and the Great Housing Reset02:00 What a housing reset really means03:30 Income growth versus home price growth05:20 Mortgage rates and the outlook for borrowing costs08:40 Fed policy, bond markets, and mortgage rates10:40 Inventory shortages and the lock in effect12:30 Regional housing market winners and losers16:00 Affordability challenges for younger buyers19:00 Rental markets and investor dynamics21:20 Multi generational living and ADUs25:00 Housing policy and supply constraints29:30 Why 50 year mortgages do not solve affordability33:00 Geographic housing outlook by life stage39:30 Climate risk, insurance, and housing costs47:00 Energy efficiency and dense housing50:20 AI, real estate search, and market structure54:30 What to watch in the housing market through 202659:30 Book discussion and where to follow Daryl Fairweather

Geographic origins and genetics of eastern and Great Lakes mallardsEric Lance is a wildlife biologist, ecologist, researcher and professor in Ohio who brings the facts about waterfowl migration and habitat to the episode, discussing the flooded corn debate and what weather patterns are changing to affect waterfowl.Lance Ecology Lab: https://www.lanceecologylab.com/Feathered Skies Podcast: https://www.instagram.com/featheredskiespodcast/?hl=hrGeographic origins and genetics of eastern and Great Lakes mallards: https://wildlife.onlinelibrary.wiley.com/doi/abs/10.1002/jwmg.70099Support this podcast at — https://redcircle.com/toomanyhobbies/donations

Send us a textThe Outlaws return with a new episode as Hughesy joins after his winter break. Top 5 - Fads from our teenage years, 5 crazy questions, over/under, this or that and rabbit holeSupport the show#outlawblitz @outlawblitz

Episode 144Happy New Year! This is one of my favorite episodes of the year — for the fourth time, Nathan Benaich and I did our yearly roundup of AI news and advancements, including selections from this year's State of AI Report.If you've stuck around and continue to listen, I'm really thankful you're here. I love hearing from you.You can find Nathan and Air Street Press here on Substack and on Twitter, LinkedIn, and his personal site. Check out his writing at press.airstreet.com.Find me on Twitter (or LinkedIn if you want…) for updates on new episodes, and reach me at editor@thegradient.pub for feedback, ideas, guest suggestions.Outline* (00:00) Intro* (00:44) Air Street Capital and Nathan world* Nathan's path from cancer research and bioinformatics to AI investing* The “evergreen thesis” of AI from niche to ubiquitous* Portfolio highlights: Eleven Labs, Synthesia, Crusoe* (03:44) Geographic flexibility: Europe vs. the US* Why SF isn't always the best place for original decisions* Industry diversity in New York vs. San Francisco* The Munich Security Conference and Europe's defense pivot* Playing macro games from a European vantage point* (07:55) VC investment styles and the “solo GP” approach* Taste as the determinant of investments* SF as a momentum game with small information asymmetry* Portfolio diversity: defense (Delian), embodied AI (Syriact), protein engineering* Finding entrepreneurs who “can't do anything else”* (10:44) State of AI progress in 2025* Momentous progress in writing, research, computer use, image, and video* We're in the “instruction manual” phase* The scale of investment: private markets, public markets, and nation states* (13:21) Range of outcomes and what “going bad” looks like* Today's systems are genuinely useful—worst case is a valuation problem* Financialization of AI buildouts and GPUs* (14:55) DeepSeek and China closing the capability gap* Seven-month lag analysis (Epoch AI)* Benchmark skepticism and consumer preferences (”Coca-Cola vs. Pepsi”)* Hedonic adaptation: humans reset expectations extremely quickly* Bifurcation of model companies toward specific product bets* (18:29) Export controls and the “evolutionary pressure” argument* Selective pressure breeds innovation* Chinese companies rushing to public markets (Minimax, ZAI)* (21:30) Reasoning models and test-time compute* Chain of thought faithfulness questions* Monitorability tax: does observability reduce quality?* User confusion about when models should “think”* AI for science: literature agents, hypothesis generation* (23:53) Chain of thought interpretability and safety* Anthropomorphization concerns* Alignment faking and self-preservation behaviors* Cybersecurity as a bigger risk than existential risk* Models as payloads injected into critical systems* (27:26) Commercial traction and AI adoption data* Ramp data: 44% of US businesses paying for AI (up from 5% in early 2023)* Average contract values up to $530K from $39K* State of AI survey: 92% report productivity gains* The “slow takeoff” consensus and human inertia* Use cases: meeting notes, content generation, brainstorming, coding, financial analysis* (32:53) The industrial era of AI* Stargate and XAI data centers* Energy infrastructure: gas turbines and grid investment* Labs need to own models, data, compute, and power* Poolside's approach to owning infrastructure* (35:40) Venture capital in the age of massive GPU capex* The GP lives in the present, the entrepreneur in the future, the LP in the past* Generality vs. specialism narratives* “Two or 20”: management fees vs. carried interest* Scaling funds to match entrepreneur ambitions* (40:10) NVIDIA challengers and returns analysis* Chinese challengers: 6x return vs. 26x on NVIDIA* US challengers: 2x return vs. 12x on NVIDIA* Grok acquired for $20B; Samba Nova markdown to $1.6B* “The tide is lifting all boats”—demand exceeds supply* (44:06) The hardware lottery and architecture convergence* Transformer dominance and custom ASICs making a comeback* NVIDIA still 90–95% of published AI research* (45:49) AI regulation: Trump agenda and the EU AI Act* Domain-specific regulators vs. blanket AI policy* State-level experimentation creates stochasticity* EU AI Act: “born before GPT-4, takes effect in a world shaped by GPT-7”* Only three EU member states compliant by late 2025* (50:14) Sovereign AI: what it really means* True sovereignty requires energy, compute, data, talent, chip design, and manufacturing* The US is sovereign; the UK by itself is not* Form alliances or become world-class at one level of the stack* ASML and the Netherlands as an example* (52:33) Open weight safety and containment* Three paths: model-based safeguards, scaffolding/ecosystem, procedural/governance* “Pandora's box is open”—containment on distribution, not weights* Leak risk: the most vulnerable link is often human* Developer–policymaker communication and regulator upskilling* (55:43) China's AI safety approach* Matt Sheehan's work on Chinese AI regulation* Safety summits and China's participation* New Chinese policies: minor modes, mental health intervention, data governance* UK's rebrand from “safety” to “security” institutes* (58:34) Prior predictions and patterns* Hits on regulatory/political areas; misses on semiconductor consolidation, AI video games* (59:43) 2026 Predictions* A Chinese lab overtaking US on frontier (likely ZAI or DeepSeek, on scientific reasoning)* Data center NIMBYism influencing midterm politics* (01:01:01) ClosingLinks and ResourcesNathan / Air Street Capital* Air Street Capital* State of AI Report 2025* Air Street Press — essays, analysis, and the Guide to AI newsletter* Nathan on Substack* Nathan on Twitter/X* Nathan on LinkedInFrom Air Street Press (mentioned in episode)* Is the EU AI Act Actually Useful? — by Max Cutler and Nathan Benaich* China Has No Place at the UK AI Safety Summit (2023) — by Alex Chalmers and Nathan BenaichResearch & Analysis* Epoch AI: Chinese AI Models Lag US by 7 Months — the analysis referenced on the US-China capability gap* Sara Hooker: The Hardware Lottery — the essay on how hardware determines which research ideas succeed* Matt Sheehan: China's AI Regulations and How They Get Made — Carnegie EndowmentCompanies Mentioned* Eleven Labs — AI voice synthesis (Air Street portfolio)* Synthesia — AI video generation (Air Street portfolio)* Crusoe — clean compute infrastructure (Air Street portfolio)* Poolside — AI for code (Air Street portfolio)* DeepSeek — Chinese AI lab* Minimax — Chinese AI company* ASML — semiconductor equipmentOther Resources* Search Engine Podcast: Data Centers (Part 1 & 2) — PJ Vogt's two-part series on XAI data centers and the AI financing boom* RAAIS Foundation — Nathan's AI research and education charity Get full access to The Gradient at thegradientpub.substack.com/subscribe

Brianne Mees, CEO of Tender Loving Empire, shares how a people-first background in psychology and social work shaped the culture of a retail brand built to champion artists, makers, and small businesses. Brianne walks through the company's growth from a scrappy early storefront to seven locations (including airport stores), the toughest leadership decisions during the pandemic, and why mission alignment is the anchor for hiring and culture. Brandon and Brianne also explore "regenerative retail," community investing through Wefunder, and how leaders can build a business that supports local economies without losing sight of sustainability and scale. Key Timestamps 00:00 What the show is about + sponsor message from Xenium HR 01:00 Introducing Brianne Mees and the Tender Loving Empire mission 03:00 Brianne's unconventional path: psychology, social work, and a people-first approach 04:40 Why Tender Loving Empire started as a "helping profession" for artists and makers 05:00 The business today: seven retail locations, hundreds of makers, and a record label 06:00 The early days: starting before major online platforms existed for creators 07:00 The turning point: moving locations, hiring the first employee, and shifting from hobby to sustainable business 08:40 How Brianne's psychology background supported hiring and leadership 09:20 Scaling a creative retail brand into airports without losing the "feel" 10:00 Becoming "Portland tour guides" and translating local culture for travelers 12:00 Leading through the pandemic: scrappiness, resilience, and hard choices 13:00 The toughest day: furloughing the team while keeping leadership in place 13:50 Post-pandemic momentum: new airport locations and +$3M in annual revenue 14:10 How they keep 65 employees aligned: mission fit and kindness 15:20 The "Empire" name origin and the heart of the brand 15:40 The impact: celebrating $20M returned to artists and makers 16:00 Vendor selection today: buying team, data-driven decisions, and mission alignment 17:00 The ripple effect: vendors who reinvest through sustainability and social impact 18:00 Geographic focus: Portland and the broader Pacific Northwest 19:00 Why music remains the heart and soul of the brand 19:10 Why Tender Loving Empire chose Wefunder and community investing 20:40 Why VC is not the right fit for a values-based retail brand 21:20 How their Wefunder raise works: $1.2M goal and a convertible note approach 23:00 Advice to her 2007 self: confidence, trusting instincts, and staying close to the core 25:00 Preparing leaders for the next growth phase: transparency and sharing the full vision 27:20 What keeps Brianne going on tough days: impact, community, and walking into the stores 28:50 "Regenerative retail" explained: supporting communities vs. extracting from them 29:50 A first step for leaders: rethink suppliers and where resources flow 30:30 AI and the creator economy: efficiency benefits vs. IP and compensation concerns 33:00 Founder advice: grit, tenacity, support systems, and learning along the way 33:40 Closing: how listeners can support Tender Loving Empire and invest (starting at $100) 34:00 Podcast disclaimer and wrap-up A QUICK GLIMPSE INTO OUR PODCAST Podcast: Transform Your Workplace, sponsored by Xenium HR Host: Brandon Laws In Brandon's own words: "The Transform Your Workplace podcast is your go-to source for the latest workplace trends, big ideas, and time-tested methods straight from the mouths of industry experts and respected thought-leaders." About Xenium HR Xenium HR is on a mission to transform workplaces by providing expert outsourced HR and payroll services for small and medium-sized businesses. With a people-first approach, Xenium helps organizations create thriving work environments where employees feel valued and supported. From navigating compliance to enhancing workplace culture, Xenium offers tailored solutions that empower growth and simplify HR. Whether managing employee relations, payroll processing, or implementing impactful training programs, Xenium is the trusted partner businesses rely on to elevate their workplace experience. Discover how Xenium can transform your workplace: Learn more [https://www.xeniumhr.com/] Connect with Brandon Laws: LinkedIn [https://www.linkedin.com/in/lawsbrandon] Instagram [https://www.instagram.com/lawsbrandon] About [https://xeniumhr.com/about-xenium/meet-the-team/brandon-laws] Connect with Xenium HR: Website [https://xeniumhr.com/] LinkedIn [https://www.linkedin.com/company/xenium-hr] Facebook [https://www.facebook.com/XeniumHR] Twitter [https://twitter.com/XeniumHR] Instagram [https://www.instagram.com/xeniumhr] YouTube [https://www.youtube.com/user/XeniumHR

Pediatrician Yair Bannett studies and treats ADHD in preschool-age children. His interests stem from watching too many families struggle to understand their child's behavior. He now focuses on improving frontline care using artificial intelligence to analyze electronic health records. One recent study explored whether doctors are making appropriate non-drug interventions before choosing to medicate children. Through his research, he hopes to raise the standard of ADHD care for thousands – and perhaps millions – of children. Early diagnosis and better care can prevent later problems, Bannett tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Episode Reference Links:Stanford Profile: ​​Yair Bannett Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Yair Bannett, a developmental behavioral pediatrician at Stanford University.(00:03:44) Why Study ADHDYair's path from primary care pediatrics to ADHD research.(00:04:32) Understanding ADHDThe core symptoms and diagnostic criteria for ADHD.(00:05:57) Diagnosing ADHD in YouthWhy diagnosis is challenging and relies on clinical judgment.(00:08:21) Known Causes of ADHDWhat is known about biological origins and environmental influence.(00:10:08) Geographic and Cultural DifferencesThe variations in ADHD prevalence across regions and populations.(00:11:37) ADHD Across CountriesPrevalence of ADHD globally and challenges with monitoring diagnosis.(00:12:23) Natural History of Untreated ADHDThe lifelong persistence of ADHD and associated risks when untreated.(00:14:28) ADHD Diagnosis in AdultsThe challenges in identifying and diagnosing ADHD later in life.(00:16:27) ADHD TreatmentsAn overview of the two treatment interventions used to treat ADHD.(00:18:16) Stimulant MedicationsThe effectiveness and long-term benefits of stimulant treatments.(00:21:30) Non-Stimulant MedicationsWhen and why alternative medications for ADHD are used.(00:22:31) Non-pharmacological InterventionsThe alternative interventions used outside pharmacological treatments.(00:23:18) Reducing Household ChaosStrategies for structure and behavior management within the home.(00:24:55) Measuring Quality of ADHD CareUsing electronic health records and AI to improve treatment.(00:28:10) Importance of Early DiagnosisThe benefits of identifying ADHD before school entry.(00:29:29) Future In a MinuteRapid-fire Q&A: applying AI, collaboration, and theatre dreams.(00:31:55) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, I'm joined by Virginie Raphael — investor, entrepreneur, and philosopher of work — for a wide-ranging conversation about incentives, technology, and how we build systems that scale without losing their humanity. We talk about her background growing up around her family's flower business, and how those early experiences shaped the way she thinks about labor, value, and operating in the real economy. That foundation carries through to her work as an investor, where she brings an operator's lens to evaluating businesses and ideas. We explore how incentives quietly shape outcomes across industries, especially in healthcare. Virginie shares why telehealth was a meaningful shift and what needs to change to move beyond one-to-one, supply-constrained models of care. We also dig into AI, venture capital, and the mistakes founders commonly make today — from hiring sales teams too early to raising too much money too fast. Virginie offers candid advice on pitching investors, why thoughtful cold outreach still works, and how doing real research signals respect and fit. The conversation closes with a contrarian take on selling: why it's not a numbers game, how focus and pre-qualification drive better outcomes, and why knowing who not to target is just as valuable as finding the right people. If you're thinking about the future of work, building with intention, or navigating entrepreneurship in an AI-accelerated world, this episode is for you. And for more conversations like this, join us at Snafu Conference 2026 on March 5th, where we'll keep exploring incentives, human skills, and what it really takes to build things that last. Start (0:00) Reflections on Work, Geography, and AI Adoption Virginie shares what she's noticing as trends in work and tech adoption: Geographic focus: she's excited to explore AI adoption outside traditional tech hubs. Examples: Atlanta, Nashville, Durham, Utah, Colorado, Georgia, North Carolina, parts of the Midwest. Rationale: businesses in these regions may adopt AI faster due to budgets, urgency, and impatience for tech that doesn't perform. "There are big corporates, there are middle and small businesses in those geos that have budget that will need the tech… and/or have less patience, I should say, for over-hub technologies that don't work." She notes that transitions to transformational technology never happen overnight, which creates opportunities: "We always underestimate how much time a transition to making anything that's so transformational… truly ubiquitous… just tends to think that it will happen overnight and it never does." Robin adds context from her own experience with Robin's Cafe and San Francisco's Mission District: Observed cultural and business momentum tied to geography Mentions Hollywood decline and rise of alternative media hubs (Atlanta, Morocco, New Jersey) Virginie reflects on COVID's impact on workforce behaviors: Opened a "window" to new modes of work and accelerated change: "There were many preexisting trends… but I do think that COVID gave a bit of a window into what was possible." Emphasis on structural change: workforce shifts require multi-year perspective and infrastructure, not just trends. Investor, Mission, and Capital Philosophy Virginie clarifies she is an investor, not a venture capitalist, resisting labels and prestige metrics. "I don't call myself a venture capitalist… I just say investor." Focuses on outcomes over categories, investing in solutions that advance the world she wants to see rather than chasing trendy tech sectors. "The outcome we want to see is everyone having the mode of work that suits them best throughout their lives." Portfolio themes: Access: helping people discover jobs they wouldn't otherwise know about. Retention / support: preventing workforce dropouts, providing appropriate healthcare, childcare, and caregiving support. "Anyone anywhere building towards that vision is investible by us." Critiques traditional venture capital practices: Raising VC money is not inherently a sign of success. "Raising from a VC is just not a sign of success. It's a milestone, not the goal." Concerned about concentration of capital into a few funds, leaving many founders unsupported. "There's a sense… that the work we do commands a lot less power in the world, a lot less effectiveness than holding the capital to hire that labor." Emphasizes structural, mission-driven investing over chasing categories: Invests in companies that prevent workforce dropouts, expand opportunity, and create equitable access to meaningful work. Portfolio strategy is diversified, focusing on infrastructure and long-term impact rather than quick wins. "We've tracked over time what type of founders and what type of solutions we attract and it's exactly the type of deal that we want to see." Reflects on COVID and societal trends as a lens for her investment thesis: "COVID gave a bit of a window into what was possible," highlighting alternative modes of work and talent distribution that are often overlooked. Labor, Ownership, and Durable Skills Virginie reframes the concept of labor, wages, and ownership: "The word labor in and of itself… is something we need to change." Interested in agency and ownership as investment opportunities, especially for small businesses transitioning to employee ownership. "For a very long time… there's been a shift towards knowledge work and how those people are compensated. If you go on the blue-collar side… it's about wages still and labor." Emphasizes proper capitalization and alignment of funds to support meaningful exits for smaller businesses, rather than chasing massive exits that drive the VC zeitgeist. AI fits into this discussion as part of broader investment considerations. Childhood experience in family flower business shaped her entrepreneurial and labor perspective: Selling flowers, handling cash, and interacting with customers taught "durable skills" that persisted into adulthood. "When I think of labor, I think of literally planting pumpkin plants… pulling espresso shots… bringing a customer behind the counter." Observing her father start a business from scratch instilled risk-taking and entrepreneurial spirit. "Seeing my dad do this when I was seven… definitely part of that." Skills like sales acumen, handling money, and talking to adults were early lessons that translated into professional confidence. Non-linear career paths and expanding exposure to opportunity: Concerned that students often see only a narrow range of job options: "Kids go out of high school, they can think of three jobs, two of which are their parents' jobs… Surely because we do a poor job exposing them to other things." Advocates for creating more flexible and exploratory career pathways for young people and adults alike. Durable skills and language shaping work: Introduction of the term "durable skills" reframes how competencies are understood: "I use it all the time now… as a proof point for why we need to change language." Highlights the stigma and limitations of words like "soft skills" or "fractional work": Fractional roles are high-impact and intentional, not temporary or inferior. "Brilliant people who wanna work on a fractional basis… they truly wanna work differently… on a portfolio of things they're particularly good at solving." Work in Progress uses language intentionally to shift perceptions and empower people around work. Cultural significance of language in understanding work and people: Virginie notes that language carries stigma and meaning that shapes opportunities and perception. References Louis Thomas's essays as inspiration for attention to the nuance and power of words: He'll take the word discipline and distill it into its root, tie it back into the natural world." Robin shares a personal anecdote about language and culture: "You can always use Google Translate… but also it's somebody learning DIA or trying to learn dharia, which is Moroccan Arabic… because my fiance is Moroccan." Human-Positive AI, Process, and Apprenticeship Virginie emphasizes the value of process over pure efficiency, especially in investing and work: "It's not about the outcome often, it's about the process… there is truly an apprenticeship quality to venture and investing." Using AI to accelerate tasks like investment memos is possible, but the human learning and iterative discussion is critical: "There's some beauty in that inefficiency, that I think we ought not to lose." AI should augment human work rather than replace the nuanced judgment, particularly in roles requiring creativity, judgment, and relationship-building: "No individual should be in a job that's either unsafe or totally boring or a hundred percent automatable." Introduces the term "human-positive AI" to highlight tools that enhance human potential rather than simply automate tasks: "How do we use it to truly augment the work that we do and augment the people?" Project selection and learning as a metric of value: Virginie evaluates opportunities not just on outcome, but what she will learn and who she becomes by doing the work: "If this project were to fail, what would I still learn? What would I still get out of it?" Cites examples like running a one-day SNAFU conference to engage people in human-centered selling principles: "Who do I become as a result of doing that is always been much more important to me than the concrete outcomes of this thing going well." AI Bubble, Transition, and Opportunity Discusses the current AI landscape and the comparison to past tech bubbles: "I think we're in an AI bubble… 1999 was a tech bubble and Amazon grew out of it." Differentiates between speculative hype and foundational technological transformation: "It is fundamental. It is foundational. It is transformative. There's no question about that." Highlights the lag between technological introduction and widespread adoption: "There's always a pendulum swing… it takes time for massively transformative technology to fully integrate." AI as an enabler, not a replacement: Transition periods create opportunity for investment and human-positive augmentation. Examples from healthcare illustrate AI's potential when applied correctly: "We need other people to care for other people. Should we leverage AI so the doctor doesn't have to face away from the patient taking notes? Yes, ambient scribing is wonderful." Emphasizes building AI around real human use cases and avoiding over-automation: "What are the true use cases for it that make a ton of sense versus the ones we need to stay away from?" History and parallels with autonomous vehicles illustrate the delay between hype and full implementation: Lyft/Uber example: companies predicted autonomous vehicles as cost drivers; the transition opened up gig work: "I was a gig worker long before that was a term… the conversation around benefits and portability is still ongoing." AI will similarly require time to stabilize and integrate into workflows while creating new jobs. Bias, Structural Challenges, and Real-World AI Experiments Discusses the importance of addressing systemic bias in AI and tech: Shares the LinkedIn "#WearThePants" experiment: women altered gender identifiers to measure algorithmic reach: "They changed their picture, in some cases changed their names… and got much more massive reach." Demonstrates that AI can perpetuate structural biases baked into systems and historical behavior: "It's not just about building AI that's unbiased; it's about understanding what the algorithm might learn from centuries of entrenched behavior." Highlights the ongoing challenge of designing AI to avoid reinforcing existing inequities: "Now you understand the deeply structural ingrained issues we need to solve to not continue to compound what is already massively problematic." Parenting, Durable Skills, and Resilience Focus on instilling adaptability and problem-solving in children: "I refuse to problem solve for them. If they forget their homework, they figure it out, they email the teacher, they apologize the next day. I don't care. I don't help them." Emphasizes allowing children to navigate consequences themselves to build independence: "If he forgets his flute, he forgets his flute. I am not making the extra trip to school to bring him his flute." Everyday activities are opportunities to cultivate soft skills and confidence: "I let them order themselves at the restaurant… they need to look the waiter in the eye and order themselves… you need to speak more clearly or speak loudly." Cultural context and exposure shape learning: Practices like family meals without devices help children appreciate attention, respect, and communication: "No iPad or iPhone on our table… we sit properly, enjoy a meal together, and talk about things." Travel and cultural exposure are part of teaching adaptability and perspective: "We spent some time in France over the summer… the mindset they get from that is that meals matter, and people operate differently." Respecting individuality while fostering independence: "They are their own people and you need to respect that and step away… give them the ability to figure out who they are and what they like to do." Parenting as a balance of guidance and autonomy: "Feel like that was a handbook that you just offered for parenting or for management? Either one. Nobody prepares you for that… part of figuring out." Future of Work and Technology Horizons Timeframes for predicting trends: Focus on a 5-year horizon as a middle ground between short-term unpredictability and long-term uncertainty: "Five years feels like this middle zone that I'm kind of guessing in the haze, but I can kind of see some odd shapes." Short-term (6–18 months) is more precise; long-term (10–15 years) is harder to anticipate: "I'm a breezy investor. Six months at a time max… deal making between two people still matters in 18 months." Identifying emerging technologies with latent potential: Invests in technologies that are ready for massive impact but haven't yet had a "moment": "I like to look at technologies that have yet to have a moment… the combo of VR and AI is prime." Example: Skill Maker, a VR+AI training platform for auto technicians, addressing both a labor shortage and outdated certification processes: "We are short 650,000 auto technicians… if you can train a technician closer to a month or two versus two years, I promise you the auto shops are all over you." Focuses on alignment of incentives, business model innovation, and meaningful outcomes: "You train people faster, even expert technicians can benefit… earn more money… right, not as meaningful to them and not as profitable otherwise." Principles guiding technology and investment choices: Solving enduring problems rather than temporary fads: "What is a problem that is still not going to go away within the next 10–15 years?" Ensuring impact at scale while creating economic and personal value for participants: "Can make a huge difference in the lives of 650,000 people who would then have good paying jobs." Scaling, Incentives, and Opportunity Re-examining traditional practices and identifying opportunities for change: "If you've done a very specific thing the exact same way, at some point, that's prime to change." Telehealth is an example: while helpful for remote access, it hasn't fundamentally created capacity: "You're still in that one-to-one patient's relationship and an hour of your time with a provider is still an hour at a time." Next version of telehealth should aim to scale care beyond individual constraints: "Where do we take telehealth next… what is the next version of that that enables you to truly scale and change?" Incentives shape outcomes: "Thinking through that and all the incentives… if I were to change the incentives, then people would behave differently? The answer very often is yes, indeed." Paraphrasing Charlie Munger: "Look for the incentives and I can tell you the outcome." Founders, Pitching, and Common Mistakes Pet peeves in founder pitches: Lack of research and generic outreach is a major turn-off: "I can really quickly tell if you have indeed spent a fraction of a minute on my site… dear sir, automatic junk. I won't even read the thing." Well-crafted, thoughtful cold inbound pitches get attention: "Take some time. A well crafted cold inbound will get my attention… you don't need to figure out an intro." Big mistakes entrepreneurs make: Hiring too early, especially in sales: "Until you have a playbook, like don't hire a sales team… if you don't have about a million in revenue, you're probably not ready." Raising too much capital too quickly: "You get into that, you're just gonna spend a lot more time fundraising than you are building a company." Comparing oneself to others: "You don't know if it's true… there's always a backstory… that overnight success was 15 years in the making." Sales Strategy and Non-Sales Selling Approach is contrarian: focus on conversion, not volume: "It is not a numbers game. I think it's a conversion game… I would much rather spend more time with a narrower set of targets and drive better conversion." Understanding fit is key: "You gotta find your people… and just finding who is not or should not be on your list is equally valuable." Recognizes that each fund and business is unique, so a tailored approach is essential: "The pitch is better when I'm talking to the quote unquote right people in the right place about the right things." Where to Find Virginie and Her Work Resources for listeners: Full Circle Fund: fullcirclefund.io  Work in Progress: workinprogress.io  LinkedIn: Virginie Raphael  Where to Access Snafu Go to joinsnafu.com and sign up for free.  

Ann Berry is joined by Gen CEO Vincent Pilette to break down Gen's business model and growth strategy following its expansion beyond cybersecurity. The conversation covers how brands like Norton, Avast, LifeLock and MoneyLion fit together, how Gen thinks about consumer trust and how financial wellness is being integrated into its core security platform. Pilette also discusses customer adoption, global expansion and how the company evaluates future adjacencies and acquisitions.00:00 – Gen CEO Vincent Pilette joins00:41 – Gen's four business pillars and operating segments02:26 – Norton's role in consumer cybersecurity02:57 – Consumer vs. B2B2C growth strategy04:15 – Customer journeys across Norton, LifeLock, and MoneyLion05:07 – Platform integration and challenges with cross-selling06:59 – Subscriber base and membership structure07:58 – Global user scale across paid and free customers08:21 – Financial wellness adoption and growth outlook09:57 – Positioning Gen for consumers and investors12:09 – Trust-based solutions13:33 – Strategic priorities and future expansion areas17:11 – Customer demand for blockchain-based solutions18:16 – Geographic mix and international growth strategyAfter Earnings is brought to you by Stakeholder Labs and Morning Brew.For more go to https://www.afterearnings.comFollow UsX: https://twitter.com/AfterEarningsTikTok: https://www.tiktok.com/@AfterEarningsInstagram: https://www.instagram.com/afterearnings_/Reach OutEmail: afterearnings@morningbrew.com$GEN Learn more about your ad choices. Visit megaphone.fm/adchoices

Kristy Akullian of Blackrock considers AI the “best game in town,” but not the only game anymore. She highlights their actively managed AI ETF (BAI), which has themes like power generation and data center buildout. She also notes that geographic diversification is important in the AI trade and that many investors are under-exposed to international equities. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

Travis Chappell and his producer, Eric, react to a retired American couple who traded their old life in the US for a more affordable, higher-quality retirement in Malta. By downsizing their costs, leveraging rental income from their U.S. home, and tapping into cheaper healthcare and everyday expenses overseas, they've created a lifestyle they never could have afforded if they stayed put in the States. Their story is a real-world case study in using self-awareness and geography—not just income—to design a life you actually want. On this episode we talk about: How Mary and Kevin retired to Malta on Social Security and rental income Why your ideal life might be more about where you live than how much you earn The mindset shift from “big house and car” to “low overhead and freedom” Tradeoffs of retiring abroad: distance from family vs. more time and presence when you visit Countries where you can live comfortably for under $1,000 a month Why lifestyle bloat traps people in jobs they hate longer than necessary How to reverse-engineer your cost of living around the life you actually want Top 3 Takeaways You don't have to become a billionaire to live well in retirement; you may just need to move somewhere your Social Security or modest income stretches a lot further. Success starts with self-awareness—getting brutally honest about what you really want (time, freedom, experiences) instead of defaulting to status symbols like big houses and luxury cars. Geographic arbitrage is real: by lowering housing, transportation, and healthcare costs abroad, you can often buy more free time, less stress, and more meaningful time with the people you love. Notable Quotes “The choice was basically stay in the U.S. and keep working—or go to Malta and actually enjoy our retirement.” “You don't have to dedicate your life to becoming the next Steve Jobs; you just have to do the math on the life you want and engineer it on purpose.” “If you just float and let life happen to you, you get the kind of results that come from living that way—and that's not how I want to live.” ✖️✖️✖️✖️

In 1963, Dr. Chan Thomas wrote about pole shifts, mass extinctions, and Adam and Eve. The CIA classified it for 50 years. What was in the file they didn't want you to read?

Watch the full episode on our YouTube channel: youtube.com/@mreapodcastGeographic farming, done the right way, might be the biggest no-brainer in real estate. In this episode, we sit down with Jim Fagan, a Charlotte agent who built a farm so strong it delivers 44-50 percent market share in his neighborhood. He's not running a complicated strategy. He's running a *repeatable* one, and he's running it like a pro.We walk step-by-step through Jim's geographic farming system, from how to pick the right neighborhood to the monthly touches that keep him top of mind, to the real magic: front-yard community events that turn neighbors into clients.Jim also shares a deeply personal part of his story: his journey with bipolar disorder, how it reshaped his life, and why he believes people can still build a life of significance while carrying something heavy.If you want more listings, more visibility, and a farm that can feed your business for years, run this play.Resources:Read: The Millionaire Real Estate Agent by Gary Keller, Dave Jenks, and Jay Papasan  Explore: KW MAPS CoachingLearn: Command for Agents (Keller Williams) Order the Millionaire Real Estate Agent Playbook | Volume 3Connect with Jason:LinkedinProduced by NOVAThis podcast is for general informational purposes only. The views, thoughts, and opinions of the guest represent those of the guest and not Keller Williams Realty, LLC and its affiliates, and should not be construed as financial, economic, legal, tax, or other advice. This podcast is provided without any warranty, or guarantee of its accuracy, completeness, timeliness, or results from using the information.WARNING! You must comply with the TCPA and any other federal, state or local laws, including for B2B calls and texts. Never call or text a number on any Do Not Call list, and do not use an autodialer or artificial voice or prerecorded messages without proper consent. Contact your attorney to ensure your compliance.

Today's location-specific episode features Pacific Islands, a US Territory that includes American Samoa, Guam, and the Commonwealth of Northern Mariana Islands (CNMI).  Each of my location-specific podcasts is set up the same way answering the same four questions:  1) What are the basics of the in this location2) What are the nuances of this location – what is different that stands out?3) Some guidance about abandoned items left behind by a tenant in a rental inPacific Islands, a US Territory4) Where to get help in your local area in Pacific Islands, a US Territory.  Then I'll go through what I call my “Bingo Card” of standard items I see most often in tenancy laws in different locations.  This episode is NOT all inclusive – you must research further in your specific area including your County, Regional District, Parish, City or any other Governing Body that involves your rental location, but today's episode will get you started!This episode includes resources for Pacific Islands, a US Territory including:CNMI Landlord and Tenant Rental Act of 2017Marianas Office - Micronesian Legal Services CorporationU.S. Affiliated Pacific Basin Jurisdictions: Legal, Geographic and Demographic InformationU.S. Territories: Guam and Other Pacific Islands Profile - SIECUSHome - American Samoa Bar AssociationSecretary of American SamoaAmerican Samoa Legal Aid: Justice for All

Send us a textThis finale feels less like an ending and more like a graduation ceremony for everyone who has ever cared about Customer Success.In this closing chapter of the customer success playbook podcast, Kevin Metzger and Roman Trebon look back on a journey that started as a “ludicrous” idea over food and drinks and turned into a global community with nearly 13,000 downloads across countries like Australia, Israel, France, and beyond. They revisit how the show began as a simple networking experiment during a job transition and evolved into a platform for learning, connection, and real human stories behind Customer Success careers.Kevin and Roman share their favorite guests and moments—from foundational lessons on P&L and value with Dave Jackson, to onboarding excellence with Donna Weber, to conversations about imposter syndrome with Rachel Provan, and the future of AI and agents with Sam Cummings. They talk candidly about fear, courage, and the reality that neither of them knew the first thing about podcasting when they started.This episode is a reflective, warm, and occasionally cheeky goodbye to the show in its current form—and a clear pivot point toward what's coming next for both hosts, their careers, and the evolving world of Customer Success and AI.Detailed AnalysisFrom a business and leadership standpoint, this episode is a masterclass in experimentation, courage, and community-building.1. Turning a career transition into a strategic platformKevin initially launched the podcast as a networking tool while navigating a job transition. That decision paid off in multiple ways: expanded visibility, deeper relationships, and a strong professional brand. For leaders and CS professionals, this is a powerful example of turning uncertainty into leverage—using content as a strategic asset rather than just a marketing tactic.Key takeaways for operators and executives:Don't wait for the “perfect moment” to build a platform—build while you're in motion.Treat visibility, networking, and knowledge-sharing as part of your job, not an optional extra.Use long-form conversations to deepen trust with your ecosystem (customers, peers, partners, talent).2. The Customer Success community as a force multiplierRoman highlights how generous and open the Customer Success community has been—guests freely sharing their time, their expertise, and even their networks by recommending future guests. This is more than feel-good community talk; it's a blueprint for modern go-to-market.Business relevance:High-performing CS communities create compounding value: better ideas, stronger talent pipelines, and faster pattern recognition around what works.Geographic boundaries matter less when you're connecting through content; an Atlanta-based duo built a truly global audience.Investing in community creates resilience—especially in volatile job markets.3. Learning as a competitive advantage (and a personal operating system)A recurring theme in the conversation is learning: Kevin's love for learning, Roman's reflections on trying new formats, and the way every guestPlease Like, Comment, Share and Subscribe. You can also find the CS Playbook Podcast:YouTube - @CustomerSuccessPlaybookPodcastTwitter - @CS_PlaybookYou can find Kevin at:Metzgerbusiness.com - Kevin's person web siteKevin Metzger on Linked In.You can find Roman at:Roman Trebon on Linked In.

Waleed Jabsheh, CEO, International General Insurance, notes varied recovery across markets, with regions such as the Middle East failing to benefit from hardening conditions. Jabsheh spoke with AM Best TV at the Rendez-Vous de Septembre in Monte Carlo.

Dr. Steve Carver is Professor of Rewilding and Wilderness Science in the School of Geography, University of Leeds and Director of the Wildland Research Institute. He has over 30 years of experience in GIS and multi-criteria evaluation, with special interests in wilderness, wildlands, rewilding, landscape evaluation, and public participation. He has worked extensively on the […] Read full article: Episode 163: Steve Carver on the Challenges of Implementing Rewilding Goals Across Fragmented Geographic, Cultural, and Political Landscapes

#667: Home prices have outpaced wages for more than a decade, and first-time buyers are stretching further every year. Now a new idea is entering the conversation, the 50-year mortgage. It promises lower monthly payments, yet it reshapes everything from equity growth to long-term risk. In this episode we sit down with Karsten Jeske, PhD, CFA from Early Retirement Now, a former Federal Reserve economist known for forensic financial modeling. Together we walk through when a 50-year mortgage might make sense, when it clearly does not, and why the math is rarely as simple as “higher payment versus lower payment.” We also dig into how ultra-long mortgages could push home prices even higher, and what this means for today's buyers and tomorrow's retirees. If you've wondered whether extended loan terms offer real affordability or just disguise the cost, this conversation gives you a clearer lens. Key Takeaways Why stretching to a 50-year mortgage can look affordable on paper yet leave you with far slower equity growth in the years that matter most. The few cases where a longer mortgage term can support a deliberate strategy, such as freeing cash flow to invest, and why this only works for certain borrowers. How inflation, appreciation, and opportunity cost change the “true” math behind 30-year versus 50-year loans. Why ultra-long mortgages may raise home prices more than they help buyers and what this means for generational wealth. How late-life mortgage decisions, downsizing, and step-up in basis reshape your legacy far more than the length of the loan itself. Resources and Links Early Retirement Now blog, Karsten's research and mortgage modeling. Chapters Note: Timestamps are approximate and may vary greatly across listening platforms due to dynamically inserted ads. (00:00) 50-year mortgage debate begins (02:52) Karsten says it expands options for sophisticated investors (05:42) Paula focuses on owner-occupants who can't afford houses (11:03) Equity difference: $80K vs $20K after 10 years (18:26) Lower payments could fund other investments (25:17) Lenders package mortgages for institutional investors (29:18) US doesn't issue 100-year bonds despite stability (34:00) Small term premiums create huge returns (43:31) Paying more interest isn't automatically bad (48:08) First-time buyers now average age 40 (56:08) Geographic arbitrage enables mortgage payoff (01:00:20) 50-year mortgages could inflate home prices (01:04:51) Supply constraints drive housing affordability crisis (01:07:29) Fed might pause rate cuts in December Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome back to The Cashflow Project! In this episode, we're joined by Marcy Sagel, founder and principal of MSA Interiors, a leading commercial interior design firm specializing in multifamily, student housing, senior living, and affordable housing projects nationwide. With over 25 years of experience, Marcy shares her journey from discovering design as a teenager to building a successful firm through multiple market cycles. We dive into the role of design in real estate, the importance of mentorship and adaptability, and how diversification and thoughtful planning lead to long-term success. Whether you're an investor, entrepreneur, or passionate about real estate and design, this episode is full of insight and inspiration. [00:00] "Design Journey and Insights" [04:55] "Efficient Project Documentation Tips" [09:55] "Reflections on Construction Projects" [12:55] "Impactful Project Visualization Tactics" [16:06] "Outdoor Space Design Insights" [20:09] Space Planning for Long-Term Durability [20:56] Long-Term Project Functionality Planning [24:51] Development Delays and Partnerships [30:01] Geographic and Strategy Diversification [32:22] "Lesson Learned Through Diversification" [35:11] "Entrepreneurship and Importance of Community" [37:14] Adaptable Strategies for Entrepreneurs Connect with Marcy Sagel! Website LinkedIn Instagram Connect with The Cashflow Project! Website LinkedIn YouTube Facebook Instagram

This is a PSA and reminder for us all that sometimes changing our circumstances (like through a move, leaving our job or a relationship etc) really is the most compassionate, wise, and liberating choice…and sometimes it's just changing what our suffering looks like on a superficial level. I'll share my own story of leaving Alaska for Spain and jam on how to know when it's helpful to change our environment and when it's not. Plus, we'll explore how Buddhist psychology can help us discern whether to stay or go.In this episode, you will learn://The myth of the “geographical cure,” and why moving abroad rarely delivers the fresh start people imagine// Why the mind always travels with us.// How to tell the difference between suffering created by our environment and suffering created by our internal patterns.// When changing circumstances is a wise, life-supporting choice, and when it becomes avoidance in disguise.// What Buddhist teachings on emptiness and perception show us about our relationship to place.// How trauma science and positive psychology explain the limits of “starting over.”// A simple reflection practice to help you discern whether you need an internal shift, an external shift, or both.Resources:// Episode 28: Practical Emptiness// Episode 29: Should I Stay or Should I Go?// Episode 202: The Healing Power of Emptiness// If you're new to the squad, grab the Rebel Buddhist Toolkit I created at RebelBuddhist.com. It has all you need to start creating a life of more freedom, adventure, and purpose. You'll also get access to the Rebel Buddhist private group, and tune in every Wednesday as I go live with new inspiration and topics.// Want something more self-paced with access to weekly group support and getting coached by yours truly? Check out Freedom School – the community for ALL things related to freedom, inside and out. We dive into taking wisdom and applying it to our daily lives, with different topics every month. Learn more at JoinFreedomSchool.com. I can't wait to see you there!// Have you benefited from even one episode of the Rebel Buddhist Podcast? I'd love it if you could leave a 5-star review on iTunes by clicking here  or on Spotify by clicking here.

John Bailey Jones and Urvi Neelakantan discuss the decline in the movement of workers from one place to another, and possible explanations and policy solutions for the decline. Jones is vice president of microeconomic analysis and Neelakantan is a senior policy economist, both at the Federal Reserve Bank of Richmond. Full transcript and related links: https://www.richmondfed.org/podcasts/speaking_of_the_economy/2025/speaking_2025_12_03_geographic_mobility

Timecodes: 0:00 Start 00:43 Secret Lives of Mormon Wives' Fruity Pebbles Rumor 15:05 Post KFC Radio Ending Announcement Thoughts 25:51 Funny weekend stories 42:43 Joe Budden Podcast "Shoutout" 45:37 Joe Budden Show KFC Radioi "Shoutout": https://open.spotify.com/episode/26q3wiSzxgD1GUpY37S0Uo 52:18 TV Recaps 01:30:46 Looking back on the start of KFC Radio +++++++++++++++++++++++++++++++++++++++++ Gametime: Download the Gametime app today and use code KFC for $20 off your first purchase Bluechew: Use promo code KFC at https://bluechew.com for your first month FREE Kraken: Kraken: Offer begins November 5th 18:00 UTC and ends December 3rd 23:59:59 UTC. Opt-in required via the Kraken app. One entry per $1 traded on Kraken. 1,000,000 entry cap per user. Geographic restrictions apply. Terms apply: https://kraken.com/legal/bitcoin-sweepstakes-terms. PHX: USE PROMO CODE BARSTOOL5 FOR $5 OFF YOUR ORDER AT DRINKPHX.COM Aura Frames: Exclusive $35 off Carver Mat at https://on.auraframes.com/KFC. Promo Code KFCYou can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/kfcr

Ukraine as Buffer State — Mary Kissel — Kissel articulates core U.S. strategic interests in Ukraine beyond ideological commitments: Ukraine's role as a critical geographic buffer against Russian expansion into Western Europeand its status as a major agricultural producer essential for global food security and economic stability. Kissel defends U.S. diplomatic engagement with Syrian leader Al-Sharaa, arguing that countering Russian regional influence in Syriajustifies negotiating with new Damascus authorities. Kissel expresses skepticism regarding whether Al-Sharaa will fulfill counter-terrorism commitments following receipt of U.S. sanctions relief, highlighting the perennial tension between incentivizing behavioral change and verification of compliance. 1854 ODESSA

Today, we'll be tackling the future of prostate cancer care. We'll be reflecting on what prostate cancer care means in practice, how the way we think about the disease is shifting, and must continue to shift in the years ahead. Scientific advances have transformed treatment in recent years, yet the lived reality of prostate cancer still extends far beyond the clinic. The disease reshapes daily life, and may leave men and their families grappling with difficult choices about how best to manage it.  Dr. Güneş Taylor is joined by three key voices at the centre of this story, following the prostate cancer journey from diagnosis through to long-term management, and asking how patients and clinicians can work together to re-think what patient-centred care could mean in the years to come. This episode is brought to you in collaboration with Bayer, part of their Prostate Cancer Perspectives series.  PP-UN-ONC-GB-0168. November 2025 References Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263 (Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide) James D, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722 (Each year, around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.1 And the numbers are rising. Diagnoses are projected to double from 1.4 million annually in 2020 to 2.9 million by 2040) Siegel RL, et al. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33 (In the U.S., the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years, due to increasing incidence of advanced-stage disease and changing guidelines regarding the prostate specific antigen screening test, implemented in the U.S. in 2012) Dodkins J, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population based evaluation. BMJ Oncology. 2025;4:e000643 (In England, nearly one in five men only receive a diagnosis once their cancer has spread) Calvo-Schimmel A, et al. Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature. Can Oncol Nurs J. 2021;31(4):412-429 (Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Building a new wine category is not something that is easy to plan. It often is more like a startup, where belief in the product and market is just as critical as a defined strategy. That's how Luisa Amorim, CEO of Amorim Family Estates, launched Mirabilis into being an iconic still white wine of the Douro Valley. She outlines priority markets, views on scores and social media, and her belief in word of mouth marketing. Detailed Show Notes: Luisa's background: hospitality, marketing; started in the family business at 23; spent 3 years in a global rotation programAmorim Family Estates3 regions in Portugal (Douro, Dao, Alentejo)Each property has its own winery and team and does hospitality with a culture and food componentDivision of bigger Amorim cork company and familyMirabilis (part of Quinta Nova)Produced white wine from the beginning (2000)First an unoaked white, then a reserve, then Mirabilis (Latin for “marvelous”)White was not popular in Portugal at the time, production processes were not set up for whitesTook 2 years of experimentation, 1st vintage 2011 (2,000 bottles)Whites still have pricing barriers vs redsDouro white differentiation: close to Atlantic, schist soils, native grapes, and blendingIntroducing Douro whites: older people were harder to get on board, younger were more open to explorationNeed to have belief in product and its viability over having a detailed marketing planMarketing focus has been on teaching Portuguese wines (including culture and traditions)Geographic focus for MirabilisPortugal 1st - need to be well respected in the home countrySwitzerland, Benelux (lots of Michelin Star restaurants)Not Scandinavia (targeting higher end of the market)Brazil (speak Portuguese)USA, Canada5 people, based in Portugal, work internationally; travel 3-5x/year to each marketWhile design and packaging, price positioning are important, the sales team and their relationships are critical in the wine industryHaving a good wine is more important than press or reviews, people are paying less attention to reviewsConsumers now look at peers and friends for recommendations and they need to trust the wine producerSocial media - “should be doing more” - hiring younger people into marketingWine marketing needs to capture the “soul” of the wineMake things simpler, less technical talkMore provocative, “sexy” vs saying the same thing all wineries sayHas not done any paid advertisingRelies on word of mouth (people taste, buy, and talk) and partnerships Hosted on Acast. See acast.com/privacy for more information.

Vision loss is never a purely clinical journey. As Dr. Jennifer Lyerly shares at the start of this Defocus Media episode, geographic atrophy affects patients emotionally, socially, and psychologically. Optometrists, therefore, play a central role in offering meaningful support throughout the entire geographic atrophy experience—especially as new treatment options, including Izervay, enter the landscape.

Will Angus | Son of a Boy Dad #354 -- #Ad: Download the Gametime app today and use code BOYDAD for $20 off your first purchase -- #Ad: Get $10 off your first month's subscription and free shipping when you go to https://Nutrafol.com and enter the promo code BOYDAD. -- #Ad: Kraken: Offer begins November 5th 18:00 UTC and ends December 3rd 23:59:59 UTC. Opt-in required via the Kraken app. One entry per $1 traded on Kraken. 1,000,000 entry cap per user. Geographic restrictions apply. Terms apply: https://kraken.com/legal/bitcoin-sweepstakes-terms. -- #Ad: GAMBLING PROBLEM? CALL 1-800-GAMBLER, (800) 327-5050 or visit gamblinghelplinema.org (MA). Call 877-8-HOPENY/text HOPENY (467369) (NY). Please Gamble Responsibly. 888-789-7777/visit ccpg.org (CT), or visit www.mdgamblinghelp.org (MD). 21+ and present in most states. (18+ DC/KY/NH/WY). Void in ONT/OR/NH. Eligibility restrictions apply. On behalf of Boot Hill Casino & Resort (KS). Pass-thru of per wager tax may apply in IL. 1 per new customer. Must register new account to receive reward Token. Must select Token BEFORE placing min. $5 bet to receive $200 in Bonus Bets if your bet wins. Min. -500 odds req. Token and Bonus Bets are single-use and non-withdrawable. Token expires 1/11/26. Bonus Bets expire in 7 days (168 hours). Stake removed from payout. Terms: sportsbook.draftkings.com/promos. Ends 1/4/26 at 11:59 PM ET. Sponsored by DK. -- Follow us on our socials: https://linktr.ee/sonofaboydad -- Merch: https://store.barstoolsports.com/collections/son-of-a-boy-dad -- SUBSCRIBE TO THE YOUTUBE #SonOfABoyDad #BarstoolSportsYou can find every episode of this show on Apple Podcasts, Spotify or YouTube. Prime Members can listen ad-free on Amazon Music. For more, visit barstool.link/sonofaboydad

Our hosts, Omar Eltorai and Cole Perry, unpack an unexpectedly strong Q3 2025, one that defied seasonal norms and signaled potential momentum building across US commercial real estate. They break down what drove transaction growth, why large deals may have returned, and how pricing trends varied across sectors and major metros. Tune into this data-rich recap for valuable context heading into year-end.Key Moments:00:50 Overview of Q3 2025 and market environment01:28 Macroeconomic trends and Federal Reserve actions04:44 Credit and equity market performance09:13 US CRE investment and transaction market in Q311:54 Detailed analysis of CRE pricing and pacing trends20:20 Geographic differences in CRE market performance25:46 Surprising trends and insights from Q3 dataResources Mentioned:Q3 2025 US CRE Investment and Transactions Quarterly report - https://www.altusgroup.com/featured-insights/cre-transactions/Email us: altusresearch@altusgroup.comThanks for listening to the “CRE Exchange” podcast, powered by Altus Group. If you enjoyed this episode, please leave a review to help get the word out about the show. And be sure to subscribe so you never miss another insightful conversation.#CRE #CommercialRealEstate #Property

Check the episode transcript hereABOUT SCOTT SAUNDERS Scott Saunders is a Senior Vice President with Asset Preservation, Inc. (API), A subsidiary of Steward Information Services Corporation. Scott has an extensive background in IRC §1031 exchanges, having been involved in hundreds of thousands of 1031 exchanges during his 37 years in the exchange industry. Mr. Saunders presents classes on advanced §1031 exchange strategies to accountants, attorneys, financial advisors, real estate brokers and principals. Mr. Saunders received his bachelor degree in Business Economics from the University of California at Santa Barbara.  THIS TOPIC IN A NUTSHELL:  Understanding the Basics of 1031 Exchanges What qualifies as a "like-kind" property? Why 1031 exchanges are a key tool in deferring capital gains tax The role and importance of a Qualified Intermediary The 45-day identification window explained The 180-day completion requirement How to identify replacement properties Trading up from residential to commercial or multifamily Simplifying your portfolio through consolidation Geographic diversification to manage risk Reverse and build-to-suit exchanges The most common mistakes investors make during a 1031 Why early planning is crucial for a successful transaction Growing interest in DSTs (Delaware Statutory Trusts) How inflation and rising interest rates are changing investor strategy Regional investment shifts and institutional-style diversification Final Takeaways Connect with Scott   KEY QUOTE:  “Deferred taxes are dollars you can reinvest — and that's how portfolios grow faster."  ABOUT THE WESTSIDE INVESTORS NETWORK    The Westside Investors Network is your community for investing knowledge for growth. For real estate professionals by real estate professionals. This show is focused on the next step in your career... investing, for those starting with nothing to multifamily syndication.    The Westside Investors Network strives to bring knowledge and education to real estate professionals that is seeking to gain more freedom in their life. The host AJ and Chris Shepard, are committed to sharing the wealth of knowledge that they have gained throughout the years to allow others the opportunity to learn and grow in their investing. They own Uptown Properties, a successful Property Management, and Brokerage Company. If you are interested in Property Management in the Portland Metro or Bend Metro Areas, please visit www.uptownpm.com. If you are interested in investing in multifamily syndication, please visit www.uptownsyndication.com.    #1031Exchange #Reverse1031 #RealEstateInvesting #RealEstateInvestor #TaxStrategy #RealEstateTaxBenefits #RealEstatePortfolio #InvestmentProperty #ReverseExchange #CashFlowRealEstate #PassiveIncome #WealthBuilding #BuildWealth #ScaleYourPortfolio #RealEstateEducation #RentalPropertyInvesting #LongTermInvesting #WealthStrategy #GenerationalWealth #AssetProtection #TaxDeferral #PropertyInvesting #RealEstateTips #InvestorMindset #FinancialFreedom #RealEstateTaxes #CostSegregation #BonusDepreciation #SmartInvesting #RealEstateGrowth   CONNECT WITH SCOTT: LinkedIn: https://www.linkedin.com/in/scott-r-saunders-6278273      CONNECT WITH US    For more information about investing with AJ and Chris:  · Uptown Syndication | https://www.uptownsyndication.com/  · LinkedIn | https://www.linkedin.com/company/71673294/admin/   For information on Portland Property Management:  · Uptown Properties | http://www.uptownpm.com  · Youtube | @UptownProperties    Westside Investors Network  · Website | https://www.westsideinvestorsnetwork.com/  · Twitter | https://twitter.com/WIN_pdx  · Instagram | @westsideinvestorsnetwork  · LinkedIn | https://www.linkedin.com/groups/13949165/  · Facebook | @WestsideInvestorsNetwork  · Tiktok| @WestsideInvestorsNetwork  · Youtube | @WestsideInvestorsNetwork  

We discuss with Dr. Rajesh C. Rao, Leonard Miller Professor of Ophthalmology, Kellogg Eye Center, University of Michigan, the results of a Phase I trial exploring the use of stem cells injected subretinally in eyes with geographic atrophy. The results are promising.

MishiPay has scaled from processing $10 million to over $250 million in annual transactions by abandoning product purity for market pragmatism. What started as a mobile-first scan-and-go solution evolved into a comprehensive checkout platform spanning self-checkout kiosks, RFID systems, mobile POS, and traditional cash registers—now deployed across 2,000+ stores in North America, Europe, the Middle East, and Australia. In this episode of Category Visionaries, we sat down with Mustafa Khanwala, CEO and Founder of MishiPay, to dissect why the "inferior" product often wins in retail tech, how trust-building mechanics differ fundamentally across geographies, and what it actually takes to maintain startup agility at enterprise scale. Topics Discussed: The seven-year journey from consumer mobile app to B2B checkout infrastructure Why MishiPay nearly failed by over-indexing on superior UX instead of adoption curves The 2022 pivot that unlocked triple-digit revenue growth with flat headcount How checkout solution requirements vary by customer visit frequency (weekly grocery vs. annual travel retail) Trust-building in enterprise sales: face-to-face requirements in Middle Eastern markets vs. video-first Western sales cycles Delivering two-week go-live timelines and 10-minute UI changes while maintaining 99.9999% uptime AI integration strategy: internal efficiency first, then customer-facing analytics and autonomous POS management GTM Lessons For B2B Founders: Adoption friction kills better products: Mustafa spent years refusing to build self-checkout because scan-and-go was objectively superior UX. The company nearly died defending this position. "Should we have started on some of our other products in 2019 instead of 2022? Probably." The lesson isn't about building inferior products—it's about understanding that customers evaluate "better" through implementation risk, training overhead, and behavior change required. B2B founders must map the gap between current state and ideal state, then build the bridge products that de-risk each transition step, even if those bridges feel like compromises. Customer frequency determines viable solution complexity: Scan-and-go requires significant user education investment that only generates ROI with weekly-plus usage. In travel retail where 70-80% of customers visit 1-2x annually, that education cost never pays back. MishiPay now matches solution types to visit patterns: scan-and-go for high-frequency grocery, staff-assisted mobile POS for low-frequency travel retail, RFID self-checkout for mid-frequency fashion. B2B founders should calculate the learning curve payback period against actual usage frequency—if users won't encounter your product enough times to justify the learning investment, you need a different entry point regardless of how good the end-state experience is. Enterprise stability with startup agility is a wedge, not a platitude: Every vendor claims this. MishiPay operationalizes it through specific SLAs: two-week store go-lives, 10-minute button changes, two-day promotion additions, two-week payment method integration—all while maintaining 99.9999% uptime that enterprise POS demands. This isn't about "moving fast," it's about architecture decisions that enable rapid customization without stability trade-offs (mobile-first, cloud-native, API-driven). B2B founders should define their agility claims in measurable timelines and uptime guarantees, not adjectives. If you can't operationalize "flexibility" into specific hours or days for changes, it's not a differentiator. Geographic trust-building fundamentally differs in mechanism, not degree: Western enterprise sales: product merit → pilot → relationship building → expansion. Middle Eastern enterprise sales: relationship building → pilot opportunity → product merit demonstration → deal. The difference isn't relationship importance (both require it), but sequencing. Mustafa noted Middle Eastern business culture evolved from pearl diving where "their whole job was to be able to look at someone in the eyes and decide if that person was going to scam them." Face-to-face happens pre-deal in Middle East, post-deal in the West. B2B founders expanding globally must rebuild their sales motion sequencing by geography, not just translate materials or add local reps. Staff productivity scales by solving the manager's problem, not the user's pain: MishiPay's roadmap progression reveals a pattern: first solve for store staff (checkout experience), then assistant managers (store operations), then store managers (performance analytics), then HQ (multi-store optimization). Each layer up requires data aggregation from the layer below. The AI analytics launch targets store-level decisions (pricing, promotions, inventory) using transaction data from POS—this expands buyer persona from IT/Operations to Finance/Merchandising. B2B founders should map their product expansion as a vertical climb through the org chart, where each new buyer persona requires accumulated data from the previous user tier.   // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role.  Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM  

11/13/25: Northampton Author Rich Michelson on "Fannie's Big Idea" (today is the 100th anniversary!). Author Thomas Suárez on “Palestine Mapped: From the River to the Sea in Early Geographic Thought” & his Nov 19 UMass talk. Amherst author Corinne Demas on her newest novel, “Daughters” Ruth Griggs: tomorrow's Western Mass Arts Economic Impact Summit.

The Multi-Geographic War on Drugs and Latin American Politics Guest: Professor Evan Ellis Professor Evan Ellis details the complex, multi-geographic war on drugs, noting the Department of Defense is leading strikes against designated terrorist groups, including Venezuela's Cartel de Los Soles. The deployment of the USS Gerald Ford Battle Group to the Caribbean raises speculation about potential land strikes against criminal leadership in Venezuela, though this carries considerable geopolitical risks. Ellis also discusses the surprising electoral success of Argentina's President Javier Milei, which strengthens the center-right political trend across Latin America.

The Multi-Geographic War on Drugs and Latin American Politics Guest: Professor Evan Ellis Professor Evan Ellis details the complex, multi-geographic war on drugs, noting the Department of Defense is leading strikes against designated terrorist groups, including Venezuela's Cartel de Los Soles. The deployment of the USS Gerald Ford Battle Group to the Caribbean raises speculation about potential land strikes against criminal leadership in Venezuela, though this carries considerable geopolitical risks. Ellis also discusses the surprising electoral success of Argentina's President Javier Milei, which strengthens the center-right political trend across Latin America. 1910 PERU

The Multi-Geographic War on Drugs and Latin American Politics Guest: Professor Evan Ellis Professor Evan Ellis details the complex, multi-geographic war on drugs, noting the Department of Defense is leading strikes against designated terrorist groups, including Venezuela's Cartel de Los Soles. The deployment of the USS Gerald Ford Battle Group to the Caribbean raises speculation about potential land strikes against criminal leadership in Venezuela, though this carries considerable geopolitical risks. Ellis also discusses the surprising electoral success of Argentina's President Javier Milei, which strengthens the center-right political trend across Latin America.

Key Takeaways In Partnership with Astellas Geographic atrophy (GA) is advancing into everyday optometric practice—and the timing of what happens after detection matters. In this Four-Eyed Professor episode, Chris Lievens, OD, MS, FAAO, welcomes retina specialist Jessica Haynes, OD, FAAO, to explore how geographic atrophy should be identified, how to talk about it, and when […]

Crypto has spent years obsessing over tokens, airdrops, and speculation. But what about the unsexy businesses actually making money? Arthur Hayes and Adam Schlegel join Laura Shin to talk about Maelstrom's $250M private equity fund targeting crypto's most profitable, yet overlooked, companies, $50M revenue businesses with 50% margins that VCs can't touch and exchanges won't pay cash for. But while everyone frames this as just another fund, Hayes and Schlegel argue it's actually the missing piece in crypto's maturation: a cash buyer for founders who've done their time and want out without four-year earnouts.  Plus: Why Asian crypto companies with monster margins get ignored by Western capital. Thank you to our sponsors! Binance Guests: Arthur Hayes, Co-Founder of BitMEX & CIO at Maelstrom Adam Schlegel, Head of Private Equity at Maelstrom Links: Previous appearances on Unchained: The Chopping Block: Arthur Hayes & Tom Lee; Hyperliquid vs Aster, DATs & ETH Arthur Hayes and Hanson Birringer on Hyperliquid's Success (And What Could Stop It) Bloomberg: Arthur Hayes' Family Office Seeks $250M for Buyout Fund Coindesk: Arthur Hayes' Maelstrom Seeks $250M Private Equity Fund to Acquire Crypto Firms: Bloomberg Akshat's tweet announcing the fund Timestamps:

Geography buffs love to find the so-called geographic center of places like America…which is in either Kansas or South Dakota, by the way. But just where is the geographic center of Christianity in the current era? Join Kevin as we take a look at the bracing and exhilarating truth of God's geography for His people! // Download this episode's Application & Action questions and PDF transcript at whitestone.org.

Drs. Priya Vakharia and Sarwar Zahid join for a journal club discussion. Functional Benefit in Geographic Atrophy Treatment (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2839343) GLP-1 Agonists and Uveitis (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2838119) Metformin and AMD (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2838821)

Geographic atrophy of the eye is a serious, progressive form of age-related macular degeneration (AMD) that can lead to irreversible vision loss. For many years, patients who asked “what is GA?” were told there was no effective treatment. Today, with FDA-approved therapies like Izervay are designed to slow disease progression, the responsibility falls on eye care professionals to identify geographic atrophy symptoms early and ensure patients enter the right care pathway. A clear referral process between optometrists and ophthalmologists is essential to deliver the best outcomes for patients with GA in eyes.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about pegivirus's potential role in Parkinson's disease pathology, the impact of GLP-1 receptor agonistst on idiopathic intracranial hypertension, and the geographic spread of epilepsy specialists.

In this episode of the Four-Eyed Professor podcast, Dr. Chris Lievens and Dr. Jessica Steen discussed how to recognize GA, how to monitor its progression, and how to guide patients through treatment discussions. Optometrists are increasingly asked not only what IZERVAY is and what it is used for, but also practical questions about how an IZERVAY eye injection works and what patients should expect.

MUSICSabrina Carpenter's new album "Man's Best Friend" is everyone's favorite pop album lately. But one of the songs sounds awfully familiar. https://www.whiskeyriff.com/2025/09/06/sabrina-carpenters-nobodys-son-gets-compared-to-jon-pardis-heartache-medication-i-cant-unhear-it/ David Bowie was creating until his very last breath in January 2016, with his final project revealed. https://nordot.app/1336642571566646155 Dave Grohl will be honored for his volunteer work by Hope the Mission at their Hope in the City of Angels Gala October 18th at BMO Stadium in Los Angeles. https://blabbermouth.net/news/dave-grohl-to-be-honored-for-his-community-volunteer-work · RIP: Rick Davies, the singer and keyboardist who was a founding member of the group Supertramp, died on Friday at his home in Long Island. He was 81. https://www.tmz.com/2025/09/07/supertramp-founding-member-rick-davies-dies/ RIP: Mark Volman, co-founder of The Turtles and Flo & Eddie, died on Friday in Nashville after a brief and sudden illness. He was 78. Here are some of the songs he sang the vibrant harmonies on, beginning with a Billboard #1 song. · TVHere's a twist I bet you didn't see coming: Charlie Sheen has had sex with men. And yes, that's MEN, plural. He admits it in both his memoir "The Book of Sheen", which comes out tomorrow . . . and the Netflix documentary "aka Charlie Sheen", which drops on Wednesday. https://people.com/charlie-sheen-opens-up-about-sexual-encounters-with-men-in-new-memoir-and-documentary-11801842 · Kate McKinnon has something called "geographic tongue." Believe it or not, it's an actual medical condition . . . but it's harmless.· Scarlett Johansson says her husband Colin Jost will be back behind the "Weekend Update" desk for Season 51 of "Saturday Night Live". https://deadline.com/2025/09/colin-jost-return-snl-weekend-update-host-season-51-1236511082/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tonight, we'll read from “Lessons in Chalk Modeling, the New Method of Map Drawing” written by Ida Cassa Heffron and published in 1900. At the turn of the twentieth century, education was undergoing rapid changes. Teachers sought creative ways to engage students in subjects that were often taught by rote memorization. Geography, in particular, was considered a cornerstone of a well-rounded education, yet it was sometimes reduced to reciting capitals and drawing borders. Heffron's work introduced a tactile and visual method known as “chalk modeling,” in which teachers could draw raised relief maps directly on the blackboard to show mountains, rivers, and valleys in a more dynamic way. Chalk modeling made classrooms more interactive, helping students imagine landscapes and physical features in three dimensions rather than flat diagrams. It reflected the broader educational trend toward “learning by doing,” a movement championed by reformers such as John Dewey. This method not only made lessons more engaging but also encouraged observation and critical thinking—skills at the heart of geography itself. By situating geography in this more hands-on practice, Heffron's book connected everyday teaching to a field that bridges human culture and natural science. Her ideas gave teachers a practical toolkit to make the world vivid on the classroom chalkboard, turning simple white lines into whole continents of imagination. — read by 'V' — Sign up for Snoozecast+ to get expanded, ad-free access by going to snoozecast.com/plus! Learn more about your ad choices. Visit megaphone.fm/adchoices

Watch the YouTube version of this episode HEREAre you an attorney looking for strategies for content and AI? In this special LinkedIn Live episode of Law Subscribed, host Matthew Kerbis (“The Subscription Attorney”) welcomes Tyson Mutrux, co-founder of Maximum Lawyer and practicing injury attorney. They discuss the evolution of legal podcasting, the importance of delivering valuable content, and strategies for effective law firm branding.Matthew and Tyson talk about the importance of valuable content over production quality. Most people will value good content over the quality of how a video is produced. As time goes on, it is important to invest in good production equipment and tools to enhance your content. But, if your content is good and of use to people, they will listen or watch despite how it looks or sounds. As content creators and attorneys, it is important to listen to what your audience wants to learn so you can keep them engaged.As AI progresses, the types of tools will become more mainstream within law firms. Law firms are perfectly equipped to take on AI tools and integrate them into a system. Whether it be intake, case management, bookkeeping, invoicing or research, AI tools like Grammerly, Perplexity or Calendly are great for managing law firms. Matthew suggests utilizing a Roku system, where all of your favourite AI tools can be managed in one place.Take a listen to learn more!05:49 Content Value and Audience Engagement13:19 Law Firm Branding and Trade Names18:31 Geographic and Niche Branding Strategies24:42 Metaverse, Blockchain, and AI in Law36:00 Subscription Models and Tech Industry Shifts39:31 Legal AI Research Tools and Law School TrainingTune in to today's episode and checkout the full show notes here.Connect with Matthew Kerbis:Website

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3708: Colin Wright explores how our physical environment shapes our ambitions, mindset, and overall trajectory in life. He urges readers to examine whether their current geography aligns with their goals and if not, to consider bold, intentional relocation as a tool for personal growth. Read along with the original article(s) here: https://exilelifestyle.com/geography-success/ Quotes to ponder: "Where we live, the environment in which we choose to exist, has a massive impact on who we become." "Aspirations are relative to the local definition of success." "You can choose to stay and try to change the culture of a place, or you can leave and find somewhere that suits you better." Learn more about your ad choices. Visit megaphone.fm/adchoices